The Greater Philadelphia region is recognized globally as a thriving and rapidly expanding global hub for the cell and gene therapy industry. This reputation is attributable to factors that include an assemblage of word-class research institutions — several of which have a long history of R&D in cell and gene therapy — and a deep, industry-specific talent pool. The region is also known for a connected, collaborative ecosystem that includes community-driven efforts like the Cell & Gene Therapy and Connected Health Initiative. This initiative supports the advancement of the sector through communications and talent attraction efforts. Firms like IPS have the expertise to facilitate scale-up and delivery of the discoveries that improve and save lives.
IPS is a global leader in developing innovative business solutions for the biotechnology and pharmaceutical industries, providing consulting, architecture, engineering, construction management, and compliance services that allow clients to create and manufacture life-impacting products around the world. Headquartered in the Philadelphia suburb of Blue Bell, IPS has a global reach with multi-disciplined professionals worldwide.
If you’re looking to start or grow your cell therapy or gene therapy company consider Greater Philadelphia first. You’ll be in a connected, collaborative and accessible region that’s home to:
- 1st FDA-approved cell therapy
- 1st FDA-approved gene therapy
- >40 cell and gene therapy R&D firms
- Nearly 70,000 life sciences professionals
- 38 four-year colleges offering programs related to life sciences
- $2.6 billion in venture capital investment directed to cell and gene therapy companies in FY20-21
IPS is proud to be a key member of the Greater Philadelphia life sciences community, helping clients deliver new technologies and innovations in the industry. Much like the thriving and rapid expansion of the region, IPS is one of the fastest-growing companies in the AEC industry. Our world-class expertise, knowledge, and understanding of industry trends emphasize time-to-market, flexibility, and cost and schedule control to avoid costly project delays and minimize risk while building, designing, constructing, and qualifying CGMP-regulated facilities.